EUVIMEDEUVIMED entdecken
Crossref

Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer

Dan Wen, Qi Wang, Jin Ding, Zilei Wang, Shiyu Lin, Hao Zhang iD, Xiaohong Huang, Xiaokun Ma, Xingguo Hou, Suping Li, Hua Zhu iD, Zhi Yang iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Dan Wen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, T-Lymphocytes, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China, North Sichuan Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucin 17 (MUC17), a transmembrane mucin, is overexpressed in pancreatic cancer and is associated with tumor proliferation and metastasis. CD3 is an indispensable molecule on the surface of T lymphocytes, which is associated with T cell activation and participates in immune responses. Here, we developed a bispecific T-cell engager radiotracer, 89Zr-M17C3, targeting MUC17 and CD3, to enable noninvasive PET imaging of both tumor cells and T-cell infiltration in pancreatic cancer. 89Zr-M17C3 was synthesized by conjugating AMG199 with zirconium-89 and verified for its radiochemical purity and in vitro stability. The 89Zr-M17C3 probe demonstrated excellent radiochemical purity (>99%) and stability (maintained ≥99% over 120 h). Cellular uptake assays and binding affinity studies were conducted to evaluate the probe's specificity for MUC17 and CD3. Micro-PET/CT imaging and biodistribution studies were performed in MUC17-expressing nude mice and CD3 humanized mice to assess probe uptake in tumors and T-cell-infiltrated tissues. In MUC17-expressing AsPC-1 tumors, probe uptake was significantly higher than in MUC17-negative PANC-1 tumors (SUVmax: 2.26 ± 0.18 vs 1.13 ± 0.14, P < 0.001) and was confirmed to be MUC17-dependent through blocking studies. In CD3 humanized mice, the probe was able to visualize both T-cell infiltration and MUC17-positive tumors, with peak uptake in AsPC-1 tumors (SUVmax: 2.35 ± 0.46) and spleen (SUVmax: 2.19 ± 0.40) at 216 h. Immunohistochemical analysis confirmed the spatial correlation between MUC17 expression and CD3-positive T-cell infiltration in AsPC-1 tumors but not in PANC-1 tumors. In summary, the 89Zr-M17C3 radiotracer exhibited high affinity for MUC17 and CD3 and successfully differentiated MUC17-positive tumors from MUC17-negative tumors while simultaneously providing insight into the T-cell distribution. This study highlights the potential of 89Zr-M17C3 as a versatile imaging tool to support patient stratification and therapeutic monitoring in tumor-targeted immunotherapy, particularly for bispecific T-cell engager-based approaches such as AMG199.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsT-LymphocytesRadiopharmaceuticalsPositron Emission Tomography Computed TomographyAntibodies, BispecificAnimalsMiceHumansTissue DistributionCell Line, TumorZirconiumRadioisotopesCD3 ComplexMice, NudePositron-Emission TomographyFemale

Stichwörter der Autor:innen

Positron emission tomography (PET)Zr-89bispecific T-cell engager (BiTE)imagingpancreatic cancer

Substanzen

ZirconiumRadioisotopesCD3 ComplexRadiopharmaceuticalsZirconium-89Antibodies, Bispecific

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceu…

ORCID-Profile: Hao Zhang, Hua Zhu, Zhi Yang

Förderung

  • Science and Technology Department of Sichuan Province
  • National Natural Science Foundation of China
  • North Sichuan Medical College
  • Youth Talent Support Program
  • Affiliated Hospital of North Sichuan Medical 6 College Research and development project

Zitieren

APA

Wen, D., Wang, Q., Ding, J., Wang, Z., Lin, S., Zhang, H., Huang, X., Ma, X., Hou, X., Li, S., Zhu, H., & Yang, Z. (2025). Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00072

Vancouver

Wen D, Wang Q, Ding J, Wang Z, Lin S, Zhang H, et al. Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00072

BibTeX
@article{Wen2025,
  author = {Wen, Dan and Wang, Qi and Ding, Jin and Wang, Zilei and Lin, Shiyu and Zhang, Hao and Huang, Xiaohong and Ma, Xiaokun and Hou, Xingguo and Li, Suping and Zhu, Hua and Yang, Zhi},
  title = {Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00072}
}
Kostenlos starten →